NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics Ltd. has announced that it believes to have met Nasdaq’s minimum bid price requirement, with its common shares trading above $1.00 for ten consecutive days. This positive development signifies the company’s recovery in compliance with Nasdaq Listing Rule 5550(a)(2). The information has been formally filed with the SEC and is integrated into the company’s existing Registration Statements on Form F-3.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
